LU90999I2 - Escitalopram et ses sels pharmaceutiquement acceptables (cipralex) - Google Patents

Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)

Info

Publication number
LU90999I2
LU90999I2 LU90999C LU90999C LU90999I2 LU 90999 I2 LU90999 I2 LU 90999I2 LU 90999 C LU90999 C LU 90999C LU 90999 C LU90999 C LU 90999C LU 90999 I2 LU90999 I2 LU 90999I2
Authority
LU
Luxembourg
Prior art keywords
cipralex
escitalopram
pharmaceutically acceptable
acceptable salts
well
Prior art date
Application number
LU90999C
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10638616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90999(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of LU90999I2 publication Critical patent/LU90999I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Compounds (AREA)
LU90999C 1988-06-14 2003-01-15 Escitalopram et ses sels pharmaceutiquement acceptables (cipralex) LU90999I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888814057A GB8814057D0 (en) 1988-06-14 1988-06-14 New enantiomers & their isolation

Publications (1)

Publication Number Publication Date
LU90999I2 true LU90999I2 (fr) 2003-03-17

Family

ID=10638616

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90999C LU90999I2 (fr) 1988-06-14 2003-01-15 Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)

Country Status (24)

Country Link
US (2) US4943590A (fr)
EP (1) EP0347066B1 (fr)
JP (2) JP3044253B2 (fr)
AT (1) ATE119896T1 (fr)
AU (1) AU623144B2 (fr)
CA (2) CA1339452C (fr)
CY (2) CY2081B1 (fr)
DE (2) DE68921672T2 (fr)
DK (2) DK259989A (fr)
ES (1) ES2068891T4 (fr)
FI (4) FI98627C (fr)
GB (1) GB8814057D0 (fr)
GR (1) GR3015889T3 (fr)
HK (1) HK139596A (fr)
HU (1) HU211460A9 (fr)
IE (1) IE65734B1 (fr)
IL (1) IL90465A (fr)
LU (1) LU90999I2 (fr)
MX (1) MX9203346A (fr)
NL (1) NL300155I2 (fr)
NO (2) NO172892C (fr)
NZ (1) NZ229426A (fr)
PT (1) PT90845B (fr)
ZA (1) ZA894476B (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
US5665270A (en) * 1991-05-20 1997-09-09 Chisso Corporation Optically active trifluorolactic acid derivative and liquid crystal composition
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
DE4439836C1 (de) * 1994-11-08 1996-06-05 Hoechst Ag cis-4-(2,2,3,3-Tetrafluorpropoxy)-zimtsäurenitril und trans-4-(2,2,3,3-Tetrafluorpropoxy)- zimtsäurenitril und ein Verfahren zu ihrer Herstellung
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
ES2189502T3 (es) * 1998-10-20 2003-07-01 Lundbeck & Co As H Metodo para la prevencion de citalopram.
IL143422A0 (en) 1998-12-23 2002-04-21 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
CH692421A5 (de) * 1999-10-25 2002-06-14 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram.
DK1298124T3 (da) * 1999-10-25 2007-07-09 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
JP2003519136A (ja) * 1999-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
AU3033700A (en) * 2000-01-14 2001-07-24 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
AU2001242298A1 (en) 2000-03-13 2001-09-24 H Lunbeck A/S Method for the preparation of citalopram
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
KR20020080485A (ko) * 2000-03-13 2002-10-23 하. 룬트벡 아크티에 셀스카브 5-치환 1-(4-플루오로페닐)-1,3-디히드로이소벤조푸란의단계적 알킬화
ES2214400T3 (es) 2000-03-14 2004-09-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
DE10190485T1 (de) * 2000-03-16 2002-03-21 Lundbeck & Co As H Verfahren zur Herstellung von 5-Cyano-1-(4-fluorphenyl)-1,3-dihydroisobenzofuranen
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
WO2002007721A2 (fr) * 2000-07-20 2002-01-31 Lauras As Methode
CA2353693C (fr) * 2000-08-10 2003-07-22 H. Lundbeck A/S Compositions pharmaceutiques contenant du citaloprame
CA2354877C (fr) 2000-08-18 2006-05-02 H. Lundbeck A/S Methode de preparation de citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
SK284418B6 (sk) * 2000-12-28 2005-04-01 H. Lundbeck A/S Spôsob výroby citalopramu
CA2435925A1 (fr) 2001-01-30 2002-08-08 Orion Corporation Fermion Procede de preparation de 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034612A1 (es) 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
PT1522539E (pt) * 2001-07-31 2007-03-30 Lundbeck & Co As H Composição cristalina contendo escitalopram
ATE286037T1 (de) * 2001-08-02 2005-01-15 Infosint Sa Verfahren zur herstellung von 5-substituierten isobenzofuranen
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
WO2003064617A2 (fr) * 2002-01-30 2003-08-07 Montana State University Isolats de pestalotiopsis microspora et composes derives de ceux-ci
EP1346989A1 (fr) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Procede ameliore de preparation de citalopram et de bromhydrate de citalopram
CA2381341A1 (fr) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Methode de preparation et intermediaires connexes pour la synthese de l'escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
TWI306846B (en) * 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
MEP5808A (xx) * 2002-12-23 2010-02-10 Lundbeck & Co As H Ecitalopram bromhidrat i postupak za njegovo pripremanje
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
WO2004056754A1 (fr) 2002-12-23 2004-07-08 H. Lundbeck A/S Procede de preparation de citalopram diol racemique et/ou s- ou r-citalopram diols ainsi qu'utilisation de tels diols pour la preparation de citalopram racemique, r-citalopram et/ou s-citalopram
KR101076640B1 (ko) * 2002-12-23 2011-10-27 하. 룬트벡 아크티에 셀스카브 라세미 시탈로프람 디올 및/또는 ｓ― 또는 ｒ―시탈로프람디올의 제조 방법 및 라세미 시탈로프람, ｒ―시탈로프람및/또는 ｓ―시탈로프람의 제조를 위한 상기 디올의 용도
CN1761659A (zh) * 2003-03-21 2006-04-19 H·隆德贝克有限公司 用于制备西酞普兰和依他普仑的中间体
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US7019153B2 (en) 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
ES2228274B1 (es) * 2003-09-24 2006-06-01 Astur Pharma, S.A. Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram.
ES2240931T3 (es) * 2003-10-28 2005-10-16 Adorkem Technology Spa Procedimiento para la preparacion de citalopram.
US20050101666A1 (en) * 2003-11-07 2005-05-12 H. Lundbeck A/S Method of treating premenstrual dysphoric disorder with escitalopram
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005049596A1 (fr) * 2003-11-20 2005-06-02 Natco Pharma Limited Procede de preparation d'escitalopram de haute purete
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
EP1797060A2 (fr) * 2004-08-23 2007-06-20 Sun Pharmaceutical Industries Limited Procede de preparation de citalopram et d'enantiomeres
WO2006025071A1 (fr) * 2004-09-02 2006-03-09 Natco Pharma Limited Procédé de synthèse de l'escitalopram
ITMI20041872A1 (it) 2004-10-01 2005-01-01 Adorkem Technology Spa Processo per la preparazione di citalopram e di scitalopram
EP1877394A1 (fr) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Processus de preparation d'escitalopram ou de ses sels d'addition acides
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2006116170A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives de dihydrobenzofurane et utilisations de ceux-ci
BRPI0610027A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de cromano e cromeno e usos dos mesmos
CA2605554A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives d'alcanamine de benzofuranyle et leurs utilisations comme agonistes 5-ht2c
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
US20110196032A1 (en) * 2005-05-20 2011-08-11 Ashish Gogia Pharmaceutical Dosage Form of an Antidepressant
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7939680B2 (en) * 2005-07-27 2011-05-10 Aurobindo Pharma Ltd. Process for the preparation of Escitalopram
EA200801080A1 (ru) * 2005-10-14 2009-02-27 Х. Лундбекк А/С Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
CA2625835A1 (fr) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Procedes de traitement de troubles du systeme nerveux central avec une combinaison de faible dose d'escitaloprame et de bupropion
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US8252336B2 (en) * 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
EP2134325A2 (fr) * 2007-03-01 2009-12-23 Aurobindo Pharma Limited Formes posologiques solides stables d'un antidépresseur
ATE534639T1 (de) 2007-04-23 2011-12-15 Synthon Bv Verfahren zur lösung von citalopram
AU2008252631B2 (en) 2007-05-18 2012-12-20 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the S-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (fr) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Procédé de préparation d'escitalopram
EP2185155B1 (fr) * 2007-08-03 2017-10-04 Richter Gedeon Nyrt. Compositions pharmaceutiques contenant des ligands des récepteurs dopaminergiques et procédé de traitement mettant en oeuvre des ligands des récepteurs de la dopamine
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
FI121570B (fi) * 2007-09-11 2011-01-14 Lundbeck & Co As H Menetelmä essitalopraamin valmistamiseksi
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN101538257B (zh) * 2008-03-21 2012-10-17 浙江华海药业股份有限公司 一种制备西酞普兰和s-西酞普兰的方法
CN101265215B (zh) * 2008-04-18 2011-03-16 浙江奥托康制药集团股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (fr) 2008-05-07 2009-11-11 Hexal Ag Granulé comprenant de l'oxalate d'escitalopram
US20110230666A1 (en) * 2008-06-03 2011-09-22 Shodhana Laboratories Limited process for the separation of enantiomerically pure compounds
WO2010004575A2 (fr) * 2008-06-16 2010-01-14 Shodhana Laboratories Limited Préparation de l’escitalopram, ses sels et ses intermédiaires
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20100249438A1 (en) * 2009-03-30 2010-09-30 Vijaya Bhaskar Bolugoddu Preparation of escitalopram
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102757414B (zh) * 2011-04-25 2014-02-19 齐鲁制药有限公司 艾司西酞普兰草酸盐的制备方法
WO2013100870A1 (fr) 2011-12-02 2013-07-04 Mahmut Bilgic Nouvelles compositions antipsychotiques
WO2013081567A1 (fr) 2011-12-02 2013-06-06 Mahmut Bilgic Formulations antipsychotiques effervescentes
ITMI20120448A1 (it) 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
ES2881105T3 (es) * 2014-11-14 2021-11-26 Zhejiang Huahai Pharm Co Ltd Método para la resolución del producto intermedio de citalopram 5-cianodiol
EP3309142B1 (fr) 2015-06-09 2020-08-05 Zhejiang Huahai Pharmaceutical Co., Ltd Procédé de préparation d'un intermédiaire de citalopram diol
CN107311968A (zh) * 2016-03-31 2017-11-03 广州市恒诺康医药科技有限公司 西酞普兰帕莫酸盐和其结晶形态及其制备方法和用途
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
US11390597B2 (en) 2017-10-09 2022-07-19 Mark Hasleton Salt and solid state forms of escitalopram
CN111217777A (zh) 2018-11-26 2020-06-02 上海奥博生物医药技术有限公司 一种高纯度艾司西酞普兰双羟萘酸盐新的制备工艺
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
EP4277661A1 (fr) 2021-01-18 2023-11-22 Anton Frenkel Forme posologique pharmaceutique
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method

Also Published As

Publication number Publication date
NO892447L (no) 1989-12-15
DK11593A (da) 1993-02-01
DE10399030I1 (de) 2004-01-08
PT90845B (pt) 1994-11-30
CA1339568C (fr) 1997-12-02
IE891859L (en) 1989-12-14
FI98627C (fi) 1997-07-25
JP3038204B2 (ja) 2000-05-08
DE10399030I2 (de) 2004-08-12
DK259989D0 (da) 1989-05-29
FI20041359A7 (fi) 2004-10-20
NO172892B (no) 1993-06-14
DE68921672D1 (de) 1995-04-20
HK139596A (en) 1996-08-02
NL300155I2 (nl) 2005-09-01
ES2068891T3 (es) 1995-05-01
GB8814057D0 (en) 1988-07-20
JPH11292867A (ja) 1999-10-26
CA1339452C (fr) 1997-09-09
ZA894476B (en) 1990-04-25
ATE119896T1 (de) 1995-04-15
MX9203346A (es) 1992-08-31
AU623144C (en) 1990-01-04
CY2007004I2 (el) 2009-11-04
NO172892C (no) 1993-09-22
JP3044253B2 (ja) 2000-05-22
IL90465A (en) 1995-01-24
EP0347066B1 (fr) 1995-03-15
FI20000507L (fi) 2000-03-06
FI941829A0 (fi) 1994-04-20
JPH0236177A (ja) 1990-02-06
FI20041359L (fi) 2004-10-20
CY2007004I1 (el) 2009-11-04
FI892823A0 (fi) 1989-06-08
EP0347066A1 (fr) 1989-12-20
FI20000507A7 (fi) 2000-03-06
NZ229426A (en) 1990-12-21
CY2081B1 (en) 1998-10-16
DK170280B1 (da) 1995-07-24
DK11593D0 (da) 1993-02-01
NL300155I1 (nl) 2004-09-01
FI91527B (fi) 1994-03-31
FI113762B (fi) 2004-06-15
GR3015889T3 (en) 1995-07-31
US4943590A (en) 1990-07-24
FI892823L (fi) 1989-12-15
FI941829L (fi) 1994-04-20
AU623144B2 (en) 1992-05-07
IE65734B1 (en) 1995-11-15
DE68921672T2 (de) 1995-07-27
HU211460A9 (en) 1995-11-28
PT90845A (pt) 1989-12-29
AU3629589A (en) 1990-01-04
ES2068891T4 (es) 2012-02-07
USRE34712E (en) 1994-08-30
NO892447D0 (no) 1989-06-13
NO2002014I2 (no) 2005-03-21
DK259989A (da) 1989-12-15

Similar Documents

Publication Publication Date Title
LU90999I2 (fr) Escitalopram et ses sels pharmaceutiquement acceptables (cipralex)
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
ATE131161T1 (de) Substanz pf 1022, verfahren zu ihrer herstellung und diese substanz enthaltende anthelmintische zusammensetzung.
DE69201959D1 (de) Verfahren zur Herstellung von 6,12-Dihydro-6-hydroxy-cannabidiol und dessen Anwendung zur Herstellung von trans-delta-9-Tetrahydrocannabinol.
DE69738154D1 (de) Optische auflösung von methylphenidat mittels 0,0'-bisaroyl-weinsäuren
EA200000057A1 (ru) (+)-норцисаприд, пригодный для лечения нарушений, опосредованных 5-нт3 и 5-нт4 (рецепторами)
ATE132487T1 (de) Verfahren zur herstellung von substituierten piperidinen
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
IT8922075A0 (it) Processo per l'inversione stereochimica di (2s,3s)-2-ammino-3-fenil-1 ,3-propandioli nei corrispondenti enantiomeri (2r,3r)
IT1231751B (it) Procedimento per la produzione di r(+) amminocarnitina e s(-) amminocarnitina
ATE79116T1 (de) Aminosaeureester, verfahren zu ihrer herstellung und ihre verwendung.
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
ATE62237T1 (de) Chroman- und thiochroman-4-essigsaeuren, verwendbar bei der behandlung von zuckerkrankheitskomplikationen.
IT8621359A1 (it) Processo per la sintesi di acidi carbossilici
DE69200389D1 (de) Verfahren zur Herstellung von Enantiomeren von 3-Aminchromanderivaten.
MX9803646A (es) Un procedimiento para producir derivados de acido 3-fenil-1-metilendioxifenil-indano-2-carboxilico.
ATE421953T1 (de) Verfahren zur racemisierung von 1-benzyl-4-(4- fluorophenyl)-3-hydroxymethyl-1,2,3,6- tetrahydropyridin und dessen verwendung in der synthese von paroxetin